INTERESTING COMPANIES FOUND

TransCode Therapeutics (2015, Boston) – Developing therapeutics targeting microRNA (miRNAs or miRs) therapeutics that are dysregulated in metastatic cancer. Its lead candidate inhibits miRNA-10b which is a known master regulator of metastatic cell viability, migration and invasion.

HIGHLIGHTS OF THE DAY

  • AstraZeneca’s $2.7B hyperkalemia drug ZS-9 rejected again by FDA. Read More  
  • AveXis shares spike on more positive data for SMA gene therapy; Biogen stock tanks on fresh skepticism. Read More  
  • Crippled bay area pharma Threshold rockets on reverse merger deal with Molecular Templates. Read More
  • Bayer and J&J’s clot-fighter Xarelto beats aspirin at holding off repeat Venous Thromboembolism. Read More
  • Alexion, Arbutus Biopharma ink $80M Rare Disease mRNA deal. Read More

Leave a Reply